Exagen Inc banner

Exagen Inc
NASDAQ:XGN

Watchlist Manager
Exagen Inc Logo
Exagen Inc
NASDAQ:XGN
Watchlist
Price: 2.99 USD -2.92%
Market Cap: $71.9m

During the last 3 months Exagen Inc insiders have not bought any shares, and sold 103.8k USD worth of shares. The stock price has dropped by 37% over this period (open performance analysis).

The last transaction was made on Mar 3, 2026 by Aballi John , who sold 56.8k USD worth of XGN shares.

Last Transactions:
Aballi John
$-56.8k
Black Jeffrey G.
$-5.7k
Aballi John
$-41.3k
Aballi John
$-375.6k
Black Jeffrey G.
$-200.4k
Nmsic Co-Investment Fund, L.p.
$-1.2m
Nmsic Co-Investment Fund, L.p.
$-660k
Black Jeffrey G.
$+66.4k
Aballi John
$+68.3k
Aballi John
$+77.6k
Adawi Kamal
$-17.7k
Adawi Kamal
$-13.1k
Aballi John
$-59k
Adawi Kamal
$-8.4k
Hazeltine Mark
$-15.7k
Adawi Kamal
$-15.7k
Aballi John
$+241.2k
Johnson Wendy S.
$+14k
Tullis James L L
$-72.9k
Tullis James L L
$-23.9k
Tullis James L L
$-50.6k
Tullis James L L
$-21.5k
Tullis James L L
$-78.9k
Tullis James L L
$-162.7k
Tullis James L L
$-140.5k
Tullis James L L
$-51k
Hunt Woody L
$-448.6k
Hunt Woody L
$-380k
Hunt Holdings Limited Partnership
$-800.7k
Hunt Holdings Limited Partnership
$-484k
Hunt Holdings Limited Partnership
$-480k
Tullis James L L
$-4k
View All Transactions

During the last 3 months Exagen Inc insiders have not bought any shares, and sold 103.8k USD worth of shares. The stock price has dropped by 37% over this period (open performance analysis).

The last transaction was made on Mar 3, 2026 by Aballi John , who sold 56.8k USD worth of XGN shares.

Sold
0-3
months
103.8k USD
2
3-6
months
0 USD
0
6-9
months
576k USD
2
9-12
months
0 USD
0
Bought
0-3
months
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Exagen Inc
Insider Trading Chart

Exagen Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Exagen Inc
Last Insider Transactions

Global
Insiders Monitor

Exagen Inc
Glance View

Market Cap
71.9m USD
Industry
Biotechnology

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 219 full-time employees. The company went IPO on 2019-09-19. The firm offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The firm develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The firm's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.

XGN Intrinsic Value
3.19 USD
Undervaluation 6%
Intrinsic Value
Price $2.99

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett